The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01696591

Recruitment Status : Unknown

Verified September 2012 by Duk Lyul Na, Samsung Medical Center.
Recruitment status was: Recruiting

First Posted : October 1, 2012

Last Update Posted : October 1, 2012

Sponsor:

Collaborator:

Medipost Co Ltd.

Information provided by (Responsible Party):

Duk Lyul Na, Samsung Medical Center

Study Description

Brief Summary:

The purpose of the study is to determine the long-term safety and exploratory efficacy of NEUROSTEM®-AD, administered via an open brain surgery to subjects with dementia of the Alzheimer's type, who were eligible for and enrolled in the earlier part of the phase I. Aside from the subjects who completed the earlier part of the Phase I, 3 additional subjects with comparable demographics and disease characteristics as the treatment group will be enrolled into a control group, followed-up for 3 months, and compared for various disease progression indicators with the treatment group.

The hypothesis is that NEUROSTEM®-AD is safe and effective in the treatment of dementia of the Alzheimer's type.

Condition or disease	Intervention/treatment
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders	Biological: NEUROSTEM®-AD

Detailed Description:

This is a long-term follow up study of the earlier part of the phase I, during which the safe and effective dose(safety) of NEUROSTEM®-AD was determined for implantation into the brains of subjects with Dementia of the Alzheimer's type. Subjects with Dementia of the Alzheimer's type, who signed the informed consent form and meet the eligibility criteria, were implanted with a single dose of NEUROSTEM®-AD, hUBC-MSCs, into the brain. The subjects were hospitalized for 5 to 10 days following the surgical implantation and were observed for acute adverse events: Gradient echo MRI within the the 24 hours post-op, vital signs, clinical laboratory tests, chest x-rays within Day 2. On Day 14, DLT was assessed, and the subjects were followed up on the safety and disease progression of dementia (of the Alzheimer's type) for 12 weeks post-implantation.

In this part of the study, the subjects described above will be followed-up for upto Month 24, and 3 additional subjects with comparable demographics and disease characteristics as the treatment group (refer to Inclusion/Exclusion Criteria) will be enrolled as a control group, followed up for 3 months and compared with the treatment group for various indicators of the disease progression.

Study Design


Study Type :	Observational
Estimated Enrollment :	14 participants
Observational Model:	Case Control
Time Perspective:	Prospective
Official Title:	The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
Study Start Date :	March 2012
Estimated Primary Completion Date :	September 2013
Estimated Study Completion Date :	September 2013

Resource links provided by the National Library of Medicine

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
NEUROSTEM®-AD A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain	Biological: NEUROSTEM®-AD NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed. Other Name: human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)
Control Group A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows: Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia. For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study.

Group/Cohort

Intervention/treatment

NEUROSTEM®-AD

A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery

DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain

Biological: NEUROSTEM®-AD

NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.

Other Name: human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)

Control Group

A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:

Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.

For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study.

Outcome Measures

Primary Outcome Measures :

Safety [ Time Frame: upto 24 months post-op ]
Incidence rate ot adverse events (vital signs, physical examination, mixed lymphocyte reaction, and laboratory tests)

Secondary Outcome Measures :

Efficacy [ Time Frame: upto 24 months post-op ]
Primary Efficacy Variable:

ADAS-cog response rate, ADAS-cog response is defined as when ADAS-cog score at the end of the study is not worse than the Baseline score.

Secondary Efficacy Variables:
- Changes in Seoul Instrumental Activities of Daily Living (S-IADL)
- Changes in Mini Mental State Examination Korean verson (K-MMSE)
- Changes in Caregiver-administered Neuropsuchiatric Inventory
- Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
- Changes in CMRglc: regional cerebral metabolic rate for glucose (FDG-PET)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	50 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

The patients, who were administered with NEUROSTEM®-AD in the earlier part of the Phase I study, will be compared with the patients, who have similar demographics and disease characteristics as the subjects in the test group but have not been treated with NEUROSTEM®-AD.

Criteria

TEST GROUP

Inclusion Criteria:

Subjects who have enrolled and completed the Phase I cliical trial: The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease
Subjects who are willing to participate in the study and sign the consent form

Exclusion Criteria:

Females who are pregnant or nursing
Subjects who have participated in another clinical study within the 3 months prior to the initiation of this study
Subjects who are restricted from undergoing exams perfomed during the study (i.e. MRI, CT, or PET screening)
Subjects who the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above

CONTROL GROUP

Inclusion Criteria:

Patients with a moderate alzheimer's disease, diagnosed with a dementia of alzheimer's type, according to the DSM-VI and NINCDS-ADRDA criteria, and shows amyloid-positive in a PIB-PET

Exclusion Criteria:

Subjects with a psychological disease (i.e. depression, schizophrenia, bipolar disorder, etc)
Subjects with a dementia caused by other degenerative neurological diseases (infection of the CNS, such as HIV or Syphilis), head trauma, Creutzfeld-Jacob disease, Pick's disease, Huntington's disease, and Parkinson's disease)
Subjects with a vascular dementia as determined by the clinical criteria of DSM IV and the imaging criteria of Erkinjuntii
Subjects with severe white matter hyperintensities (WMH); Severe WMH is defined as, according to Clinical Research Center for Dementia of South Korea, a condition in which the deep white matter is 25 mm or greater and the periventricular capping/banding is 10 mm or greater in lengths.
Subjects with a history of stroke within the 3 months prior to the study enrollment
Subjects with a severe liver disease (ALT/AST values are higher than twice the normal range)
Subjects with a severe renal disease (1.5mg/dL or more of serum creatinine)
Pregnant or lactating women
Subjects with abnormal findings of the clinical laboratory values at Visit 1:
Hemoglobin < 9.5g/dL in male < 9.0 g/dL in female
Total WBC count < 3000/mm3
Total bilirubin ≥ 3 mg/dL
Subjects with a suspected active lung disease, based on the chest X-ray result at Visit 1
Females of childbearing age who does not practice medically acceptable method of contraception during the study
Subjects who have previously failed Screening for participation in this study
Subjects who have participated in another clinical study within the 3 months prior to the initiation of this study
Subjects with a bleeding disorder (platelet count < 150,000/mm3; PT ≥ 1.5; INR or aPTT ≥ 1.5 X control
Subjects with a cancer (including brain tumor)
Subjects with a history of alcohol or drug abuse
Subjects who are restricted from undergoing exams perfomed during the study (i.e. MRI, CT, or PET screening)
Patients who the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01696591

Contacts


Contact: Duk-Lyul Na, MD, PhD	+82-2-3410-3594	dukna@naver.com

Locations


Korea, Republic of
Samsung Medical Center	Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Duk L. Na, MD, PhD +82-2-3410-3594 dukna@naver.com

Sponsors and Collaborators

Duk Lyul Na

Medipost Co Ltd.

Investigators


Principal Investigator:	Duk L. Na, MD,PhD	Samsung Medical Center

More Information

Additional Information:

The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kim HJ, Seo SW, Chang JW, Lee JI, Kim CH, Chin J, Choi SJ, Kwon H, Yun HJ, Lee JM, Kim ST, Choe YS, Lee KH, Na DL. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial. Alzheimers Dement (N Y). 2015 Jul 26;1(2):95-102. doi: 10.1016/j.trci.2015.06.007. eCollection 2015 Sep.


Responsible Party:	Duk Lyul Na, Professor of Neurology, Sungkyunkwan University School of Medicine, Samsung Medical Center
ClinicalTrials.gov Identifier:	NCT01696591 History of Changes
Other Study ID Numbers:	MP-CR-007-F/U
First Posted:	October 1, 2012 Key Record Dates
Last Update Posted:	October 1, 2012
Last Verified:	September 2012

Keywords provided by Duk Lyul Na, Samsung Medical Center:


Alzheimer, Mesenchymal Stem Cells, Umbilical Cord Blood

Additional relevant MeSH terms:


Disease Alzheimer Disease Dementia Delirium Mental Disorders Psychotic Disorders Nervous System Diseases Neurodegenerative Diseases Brain Diseases Central Nervous System Diseases	Cognition Disorders Tauopathies Neurocognitive Disorders Pathologic Processes Confusion Neurobehavioral Manifestations Neurologic Manifestations Signs and Symptoms Schizophrenia Spectrum and Other Psychotic Disorders

To Top